Are there any patients with newly diagnosed GBM in whom you would adopt Early-Start TTFields based on the TRIDENT study?
Do you consider the post hoc survival benefit in the MGMT-methylated subgroup significant?
This question is part of our ASTRO 2026 collaboration, inspired by the LBA Session Presentation "TRIDENT: Phase 3 Trial of Tumor Treating Fields (TTFields) Therapy Concurrent with Temozolomide (TMZ) for Newly Diagnosed Glioblastoma (NDGBM)" by Dr. Wenyin Shi, MD, PhD
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · University of California San Diego
Answered on
The authors of EF-32/TRIDENT should be commended for performing this impressive randomized trial of an already FDA-approved therapeutic in GBM maintenance, asking the question of whether an earlier start of TTF, during chemoradiation, improves overall survival. This is also a big ask of the therapeu...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · Thomas Jefferson University Hospital
Answered on
TRIDENT did not demonstrate an overall survival advantage for early-start TTFields in the intention-to-treat population, so the results do not support routine early initiation for all patients. However, concurrent TTFields and chemoradiation were feasible and generally well tolerated. Early initiati...
Join for free or sign in to see the full answer